{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:53:29Z","timestamp":1768096409731,"version":"3.49.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012492","name":"Youth Innovation Promotion Association","doi-asserted-by":"publisher","award":["2019B090904008"],"award-info":[{"award-number":["2019B090904008"]}],"id":[{"id":"10.13039\/501100012492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81925035"],"award-info":[{"award-number":["81925035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.apsb.2022.09.011","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T13:20:07Z","timestamp":1663939207000},"page":"1828-1846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Localized delivery of nanomedicine and antibodies for combating COVID-19"],"prefix":"10.1016","volume":"13","author":[{"given":"Bin","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinran","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8915","authenticated-orcid":false,"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.09.011_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib2","unstructured":"WHO. WHO coronavirus (COVID-19) dashboard. Available from: https:\/\/covid19.who.int\/. (Accessed June 29)."},{"key":"10.1016\/j.apsb.2022.09.011_bib3","unstructured":"U.S. Food and Drug Administration. FDA approves first COVID-19 vaccine. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine."},{"key":"10.1016\/j.apsb.2022.09.011_bib4","unstructured":"Food and Drug Administration Philippines. Whole virion, inactivated corona virus vaccine [Covaxin]. Available from: https:\/\/www.fda.gov.ph\/whole-virion-inactivated-corona-virus-vaccine-covaxin\/."},{"key":"10.1016\/j.apsb.2022.09.011_bib5","unstructured":"Food and Drug Administration Philippines. SARS-CoV-2 rS protein nanoparticle vaccine [Covovax]. Available from: https:\/\/www.fda.gov.ph\/sars-cov-2-rs-protein-nanoparticle-vaccine-covovax\/."},{"key":"10.1016\/j.apsb.2022.09.011_bib6","unstructured":"U.S. Food And Drug Administration. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals."},{"key":"10.1016\/j.apsb.2022.09.011_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2022.09.011_bib8","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12274-021-3832-y","article-title":"Review: development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform","volume":"15","author":"Sa-Nguanmoo","year":"2022","journal-title":"Nano Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120686","article-title":"Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines?","volume":"603","author":"Tiboni","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/22221751.2022.2030199","article-title":"Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques","volume":"11","author":"Xu","year":"2022","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2022.09.011_bib11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.apsb.2022.09.011_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fpubh.2020.00365","article-title":"Progress in the research and development of anti-COVID-19 drugs","volume":"8","author":"Huang","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.apsb.2022.09.011_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","article-title":"The big picture on nanomedicine: the state of investigational and approved nanomedicine products","volume":"9","author":"Etheridge","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2022.09.011_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.142363","article-title":"Prospects of nanomaterials-enabled biosensors for COVID-19 detection","volume":"754","author":"Srivastava","year":"2021","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.apsb.2022.09.011_bib15","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/j.apsb.2021.04.023","article-title":"Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design","volume":"11","author":"Qiao","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.09.011_bib16","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2022.09.011_bib17","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant alpha and beta herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40005-017-0370-4","article-title":"Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics","volume":"48","author":"Choi","year":"2018","journal-title":"J Pharm Investig"},{"key":"10.1016\/j.apsb.2022.09.011_bib19","doi-asserted-by":"crossref","first-page":"26463","DOI":"10.1039\/D1RA04835J","article-title":"Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19","volume":"11","author":"Abd Elkodous","year":"2021","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2022.09.011_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrmicro775","article-title":"SARS\u2014beginning to understand a new virus","volume":"1","author":"Stadler","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib21","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/S0140-6736(13)61228-3","article-title":"MERS-CoV: in search of answers","volume":"381","author":"Petherick","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.09.011_bib22","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1021\/acsnano.0c03976","article-title":"Flexible\u00a0nanoporous template for the design and development of reusable Anti-COVID-19 hydrophobic face masks","volume":"14","author":"El-Atab","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2022.09.011_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14789450.2021.1908894","article-title":"SARS-CoV-2 infection: molecular mechanisms of severe outcomes\u00a0to suggest therapeutics","volume":"18","author":"Hartog","year":"2021","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.apsb.2022.09.011_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","volume":"7","author":"Tang","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.apsb.2022.09.011_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib27","article-title":"Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents","volume":"2","author":"Kampf","year":"2020","journal-title":"Infect Prev Pract"},{"key":"10.1016\/j.apsb.2022.09.011_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.46234\/ccdcw2020.033","article-title":"Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19)","volume":"2","author":"Zhang","year":"2020","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.apsb.2022.09.011_bib29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","volume":"158","author":"Xiao","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2022.09.011_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib31","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.09.011_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cr.2016.152","article-title":"Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding","volume":"27","author":"Gui","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib34","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib35","article-title":"Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity","volume":"96","author":"Essalmani","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2022.09.011_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","article-title":"Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib37","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.09.011_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","article-title":"AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/biology10020095","article-title":"Mucociliary respiratory epithelium integrity in molecular defense and susceptibility to pulmonary viral infections","volume":"10","author":"Adivitiya","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.apsb.2022.09.011_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12026-021-09198-0","article-title":"A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)","volume":"69","author":"Lotfi","year":"2021","journal-title":"Immunol Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib42","unstructured":"Wadman Y, Couzin-frankel J, Kaiser J, Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Available from: https:\/\/www.science.org\/content\/article\/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes."},{"key":"10.1016\/j.apsb.2022.09.011_bib43","unstructured":"GISAID. Overview of variants\/mutations. Available from: https:\/\/covariants.org\/variants."},{"key":"10.1016\/j.apsb.2022.09.011_bib44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.09.011_bib46","unstructured":"Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19, countries of the UK, 9 February 2021. Available from:https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/articles\/coronaviruscovid19infectionsinthecommunityinengland\/characteristicsofpeopletestingpositiveforcovid19inengland9february2021 (Accessed April 22)."},{"key":"10.1016\/j.apsb.2022.09.011_bib47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S1473-3099(21)00290-5","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study","volume":"21","author":"Bager","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.apsb.2022.09.011_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib51","series-title":"Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2","author":"Pearson","year":"2021"},{"key":"10.1016\/j.apsb.2022.09.011_bib52","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021","volume":"26","author":"Funk","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.apsb.2022.09.011_bib53","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.09.011_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.09.011_bib55","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib56","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.15585\/mmwr.mm7028e2","article-title":"SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 outbreak associated with a gymnastics facility\u2014Oklahoma, April-May 2021","volume":"70","author":"Dougherty","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.apsb.2022.09.011_bib58","article-title":"Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)","author":"Ong","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2022.09.011_bib59","article-title":"Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada","author":"Fisman","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.apsb.2022.09.011_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib61","article-title":"Omicron Impact in India: analysis of the ongoing COVID-19 third wave based on global data","author":"Ranjan","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.apsb.2022.09.011_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/jcm11010030","article-title":"Relative reproduction number of SARS-CoV-2 Omicron (B.1.1.529) compared with Delta variant in South Africa","volume":"11","author":"Nishiura","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.09.011_bib64","article-title":"Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron","author":"Wang","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.apsb.2022.09.011_bib65","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1016\/S2214-109X(22)00114-0","article-title":"Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study","volume":"10","author":"Jassat","year":"2022","journal-title":"Lancet Glob Health."},{"key":"10.1016\/j.apsb.2022.09.011_bib66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/jamp.2020.1622","volume":"33","author":"Mitchell","year":"2020","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.apsb.2022.09.011_bib69","unstructured":"Phase I\/II clinical trial of recombinant novel coronavirus (COVID-19) vaccine (Adenovirus Type 5 Vector) for inhalation. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04840992."},{"key":"10.1016\/j.apsb.2022.09.011_bib70","unstructured":"Ivermectin nasal spray for COVID19 patients. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510233."},{"key":"10.1016\/j.apsb.2022.09.011_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121688","article-title":"Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment","volume":"619","author":"Albariqi","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jiac.2020.04.007","article-title":"Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases","volume":"26","author":"Iwabuchi","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.apsb.2022.09.011_bib73","article-title":"Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes","volume":"2018","author":"Borghardt","year":"2018","journal-title":"Cancer Res J"},{"key":"10.1016\/j.apsb.2022.09.011_bib74","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.09.011_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1208\/s12249-021-02043-5","article-title":"Spray-dried inhalable powder formulations of therapeutic proteins and peptides","volume":"22","author":"Eedara","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2022.09.011_bib76","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1208\/s12249-018-1183-0","article-title":"Nucleic acid-based therapeutics for pulmonary diseases","volume":"19","author":"Chen","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2022.09.011_bib77","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41467-020-14344-7","article-title":"Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis","volume":"11","author":"Dinh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.09.011_bib78","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apsb.2021.08.009","article-title":"Pulmonary delivery of siRNA against acute lung injury\/acute respiratory distress syndrome","volume":"12","author":"Zoulikha","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.09.011_bib79","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14760584.2014.915753","article-title":"Current progress in pulmonary delivery of measles vaccine","volume":"13","author":"Griffin","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.apsb.2022.09.011_bib80","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fsc.2004.04.001","article-title":"Nasal anatomy and physiology","volume":"12","author":"Lane","year":"2004","journal-title":"Facial Plast Surg Clin North Am"},{"key":"10.1016\/j.apsb.2022.09.011_bib81","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib82","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range 0.005\u201315 \u03bcm","volume":"17","author":"Heyder","year":"1986","journal-title":"J Aerosol Sci"},{"key":"10.1016\/j.apsb.2022.09.011_bib83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/cpf.12085","article-title":"Mucociliary clearance: pathophysiological aspects","volume":"34","author":"Munkholm","year":"2014","journal-title":"Clin Physiol Funct Imag"},{"key":"10.1016\/j.apsb.2022.09.011_bib84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","article-title":"A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung","volume":"75","author":"Nassimi","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1773-2247(11)50052-8","article-title":"In\u00a0vivo safety and particokinetics of inhaled nanomedicines","volume":"21","author":"Jones","year":"2011","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2022.09.011_bib86","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0035-1555612","article-title":"Novel aerosol delivery devices","volume":"36","author":"Singh","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib87","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/erv.12.31","article-title":"Mucosal immunity and nasal influenza vaccination","volume":"11","author":"Rose","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.apsb.2022.09.011_bib88","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib89","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib90","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib91","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4168\/aair.2019.11.3.306","article-title":"Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency","volume":"11","author":"Jiao","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/107175499266823","article-title":"Toxicological implications of nasal formulations","volume":"6","author":"Quadir","year":"1999","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2022.09.011_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12989-020-0339-8","article-title":"Assessment of respiratory and systemic toxicity of Benzalkonium chloride following a 14-day inhalation study in rats","volume":"17","author":"Choi","year":"2020","journal-title":"Part Fibre Toxicol"},{"key":"10.1016\/j.apsb.2022.09.011_bib94","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0149-2918(04)90050-1","article-title":"Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review","volume":"26","author":"Stanaland","year":"2004","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.apsb.2022.09.011_bib95","first-page":"93","article-title":"Addressing the regulatory and scientific challenges with generic orally inhaled drug products","volume":"34","author":"Newman","year":"2020","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib96","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1111\/bph.15621","article-title":"Lung pharmacokinetics of inhaled and systemic drugs: a clinical evaluation","volume":"178","author":"Sadiq","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2022.09.011_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2022.09.011_bib98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2018.04.003","article-title":"Development of spray-freeze-dried siRNA\/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity","volume":"279","author":"Okuda","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.09.011_bib99","series-title":"Draft guidance for industry: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action","year":"2003"},{"key":"10.1016\/j.apsb.2022.09.011_bib100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40261-016-0441-8","article-title":"Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers","volume":"36","author":"Algorta","year":"2016","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.apsb.2022.09.011_bib101","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00228-001-0382-9","article-title":"Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser","volume":"57","author":"Silkstone","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2022.09.011_bib102","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/dmd.107.015966","article-title":"A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes","volume":"35","author":"Somers","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2022.09.011_bib103","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","article-title":"Drug metabolism in the lungs: opportunities for optimising inhaled medicines","volume":"17","author":"Enlo-Scott","year":"2021","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.apsb.2022.09.011_bib104","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/20024091064273","article-title":"Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung","volume":"32","author":"Hukkanen","year":"2002","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.apsb.2022.09.011_bib105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2022.09.011_bib106","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1124\/jpet.102.038208","article-title":"Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells","volume":"304","author":"Hukkanen","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib107","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s00204-019-02602-7","article-title":"Xenobiotica-metabolizing enzymes in the lung of experimental animals, man and in human lung models","volume":"93","author":"Oesch","year":"2019","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.apsb.2022.09.011_bib108","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejps.2016.10.027","article-title":"Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs","volume":"96","author":"Patel","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2022.09.011_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pupt.2019.02.001","article-title":"Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy","volume":"55","author":"Zhu","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4155\/bio.11.325","article-title":"Towards single-cell analysis for pharmacokinetics","volume":"4","author":"Luo","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.apsb.2022.09.011_bib111","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejpb.2005.02.010","article-title":"Human respiratory epithelial cell culture for drug delivery applications","volume":"60","author":"Forbes","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib112","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/excr.1998.4172","article-title":"Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism","volume":"243","author":"Foster","year":"1998","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib113","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00441-002-0548-5","article-title":"Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: implications for the use of this cell line as an in\u00a0vitro model for bronchial drug absorption studies","volume":"308","author":"Ehrhardt","year":"2002","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib114","first-page":"L347","article-title":"Culture and transformation of human airway epithelial cells","volume":"268","author":"Gruenert","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00452-X","article-title":"Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery","volume":"208","author":"Foster","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib116","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s11095-006-0255-0","article-title":"Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier","volume":"23","author":"Grainger","year":"2006","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.apsb.2022.09.011_bib117","doi-asserted-by":"crossref","first-page":"L1002","DOI":"10.1152\/ajplung.00260.2003","article-title":"Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules","volume":"286","author":"Lombry","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejpb.2014.12.001","article-title":"Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome","volume":"89","author":"Patel","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003941","article-title":"Multiscale Co-reconstruction of lung architectures and inhalable materials spatial distribution","volume":"8","author":"Sun","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2022.09.011_bib120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/B978-0-08-034185-9.50046-2","article-title":"Particle size-selective sampling in the workplace: rationale and recommended techniques","author":"Phalen","year":"1988","journal-title":"Inhaled Particles VI"},{"key":"10.1016\/j.apsb.2022.09.011_bib121","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles\u2014a current review","volume":"356","author":"Yang","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2022.09.011_bib122","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jconrel.2022.05.006","article-title":"Exploring the intrinsic micro-\/nanoparticle size on their in\u00a0vivo fate after lung delivery","volume":"347","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.09.011_bib123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2022.09.011_bib124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2006.12.011","article-title":"Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies","volume":"362","author":"Kuate","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.apsb.2022.09.011_bib125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41467-021-27893-2","article-title":"Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2","volume":"13","author":"El-Shennawy","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.09.011_bib126","article-title":"Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID-19 therapy","volume":"33","author":"Xie","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2022.09.011_bib127","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12179","article-title":"Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection","volume":"11","author":"Kim","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.apsb.2022.09.011_bib128","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.apsb.2021.09.004","article-title":"Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.09.011_bib129","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1097\/CCM.0000000000004315","article-title":"Mesenchymal stem cell-derived extracellular vesicles alleviate acute lung injury via transfer of miR-27a-3p","volume":"48","author":"Wang","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259732","article-title":"Mesenchymal stromal cell-derived extracellular vesicles reduce lung inflammation and damage in nonclinical acute lung injury: implications for COVID-19","volume":"16","author":"Cloer","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.09.011_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.699929","article-title":"The potential role of extracellular vesicles in COVID-19 treatment: opportunity and challenge","volume":"8","author":"Yan","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2022.09.011_bib132","doi-asserted-by":"crossref","unstructured":"Chu M, Wang H, Bian L, Huang J, Wu D, Fei F, et\u00a0al. Nebulization therapy for COVID-19 pneumonia with embryonic mesenchymal stem cells-derived exosomes. Available from: https:\/\/doi.org\/10.2139\/ssrn.3678558.","DOI":"10.2139\/ssrn.3678558"},{"key":"10.1016\/j.apsb.2022.09.011_bib133","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2022.09.011_bib134","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s40820-019-0330-9","article-title":"Cell membrane coating technology: a promising strategy for biomedical applications","volume":"11","author":"Liu","year":"2019","journal-title":"Nano-Micro Lett"},{"key":"10.1016\/j.apsb.2022.09.011_bib135","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/acs.nanolett.0c02278","article-title":"Cellular nanosponges inhibit SARS-CoV-2 infectivity","volume":"20","author":"Zhang","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2022.09.011_bib136","article-title":"Inhalable nanocatchers for SARS-CoV-2 inhibition","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.09.011_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155151","article-title":"COVID-19 cytokine storm: the anger of inflammation","volume":"133","author":"Mahmudpour","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.apsb.2022.09.011_bib138","doi-asserted-by":"crossref","first-page":"27141","DOI":"10.1073\/pnas.2014352117","article-title":"Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines","volume":"117","author":"Rao","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.09.011_bib139","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.matt.2021.09.022","article-title":"Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm","volume":"5","author":"Wang","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.apsb.2022.09.011_bib140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41579-018-0112-2","article-title":"Types and origins of bacterial membrane vesicles","volume":"17","author":"Toyofuku","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib141","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev-micro-052821-031444","article-title":"Bacterial outer membrane vesicles: from discovery to applications","volume":"75","author":"Sartorio","year":"2021","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.752739","article-title":"An intranasal vaccine based on outer membrane vesicles against SARS-CoV-2","volume":"12","author":"Thapa","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2022.09.011_bib143","unstructured":"U.S. Food and Drug Administration. Coronavirus disease 2019 (COVID-19). Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/counterterrorism-and-emerging-threats\/coronavirus-disease-2019-covid-19."},{"key":"10.1016\/j.apsb.2022.09.011_bib144","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jconrel.2021.05.024","article-title":"The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2","volume":"335","author":"Huang","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2022.09.011_bib145","unstructured":"Bio T. Translate bio announces results from second interim data analysis from ongoing phase 1\/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). Available from: https:\/\/investors.translate.bio\/news-releases\/news-release-details\/translate-bio-announces-results-second-interim-data-analysis."},{"key":"10.1016\/j.apsb.2022.09.011_bib146","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2022.09.011_bib147","article-title":"Inhalable polymer nanoparticles for versatile mRNA delivery\u00a0and mucosal vaccination","author":"Suberi","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2022.09.011_bib148","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.matt.2021.04.005","article-title":"Nanotraps for the containment and clearance of SARS-CoV-2","volume":"4","author":"Chen","year":"2021","journal-title":"Matter"},{"key":"10.1016\/j.apsb.2022.09.011_bib149","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2022.09.011_bib150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2016-0068","article-title":"Intranasal delivery of nanoparticle-based vaccines","volume":"8","author":"Marasini","year":"2017","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2022.09.011_bib151","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/vaccines9070768","article-title":"Intranasal administration of RBD nanoparticles confers induction of mucosal and systemic immunity against SARS-CoV-2","volume":"9","author":"Jearanaiwitayakul","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.apsb.2022.09.011_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms","volume":"298","author":"Paiardi","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.09.011_bib153","doi-asserted-by":"crossref","first-page":"17615","DOI":"10.1021\/jacs.1c07798","article-title":"Surface glycan modification of cellular nanosponges to promote SARS-CoV-2 inhibition","volume":"143","author":"Ai","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2022.09.011_bib154","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/j.apsb.2022.01.019","article-title":"Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants","volume":"12","author":"Tu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.09.011_bib155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","article-title":"Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment","volume":"16","author":"Vartak","year":"2021","journal-title":"in\u00a0vitro. Nanomedicine"},{"key":"10.1016\/j.apsb.2022.09.011_bib156","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/pharmaceutics12111002","article-title":"Development of remdesivir as a dry powder for inhalation by thin film freezing","volume":"12","author":"Sahakijpijarn","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2022.09.011_bib157","article-title":"Silver nanoparticles: synthesis, properties, toxicology, applications and perspectives","volume":"4","author":"Tran","year":"2013","journal-title":"Adv Nat Sci"},{"key":"10.1016\/j.apsb.2022.09.011_bib158","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00204-021-03191-0","article-title":"Kinetic time courses of inhaled silver nanoparticles in rats","volume":"96","author":"Andriamasinoro","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.apsb.2022.09.011_bib159","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2147\/IJN.S53622","article-title":"Inhibition of A\/Human\/Hubei\/3\/2005 (H3N2) influenza virus infection by silver nanoparticles in\u00a0vitro and","volume":"8","author":"Xiang","year":"2013","journal-title":"in\u00a0vivo. Int J Nanomedicine"},{"key":"10.1016\/j.apsb.2022.09.011_bib160","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/v11080732","article-title":"Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection","volume":"11","author":"Morris","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2022.09.011_bib161","volume":"vol. 13","author":"Pilaquinga","year":"2021"},{"key":"10.1016\/j.apsb.2022.09.011_bib162","article-title":"Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital","author":"Zachar","year":"2020","journal-title":"ScienceOpen Preprints"},{"key":"10.1016\/j.apsb.2022.09.011_bib163","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41565-022-01177-2","article-title":"A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination","volume":"17","author":"Zhang","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2022.09.011_bib164","doi-asserted-by":"crossref","first-page":"17582","DOI":"10.1021\/acsnano.1c05002","article-title":"Gold-nanostar-chitosan-mediated delivery of SARS-CoV-2 dNA vaccine for respiratory mucosal immunization: development and proof-of-principle","volume":"11","author":"Kumar","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2022.09.011_bib165","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acsnano.0c03822","article-title":"Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles","volume":"14","author":"Moitra","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2022.09.011_bib166","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1021\/acsnano.0c02439","article-title":"Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection","volume":"14","author":"Qiu","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2022.09.011_bib167","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib168","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","article-title":"COVID-19 antibodies on trial","volume":"38","author":"DeFrancesco","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2022.09.011_bib169","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","article-title":"Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants","volume":"595","author":"Ku","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib171","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-022-00911-5","article-title":"Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib172","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features\u00a0and therapeutic potential","volume":"45","author":"Konning","year":"2017","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.apsb.2022.09.011_bib173","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies(R) as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2022.09.011_bib174","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.apsb.2022.09.011_bib175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antib8010013","article-title":"Nanobody engineering: toward next generation immunotherapies and immunoimaging of Cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.apsb.2022.09.011_bib176","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2022.09.011_bib177","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.09.011_bib178","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.abe3255","article-title":"An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike","volume":"370","author":"Schoof","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.apsb.2022.09.011_bib179","first-page":"101","article-title":"A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential","volume":"2021","author":"Gai","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.apsb.2022.09.011_bib180","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh0319","article-title":"Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses","volume":"7","author":"Nambulli","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2022.09.011_bib181","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79036-0","article-title":"High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme","volume":"10","author":"Esparza","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.09.011_bib182","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.09.011_bib183","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib184","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","article-title":"Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry","volume":"12","author":"Ge","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.09.011_bib185","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","article-title":"Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species","volume":"54","author":"Wang","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2022.09.011_bib186","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.cell.2022.03.009","article-title":"Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.09.011_bib187","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.drudis.2018.05.017","article-title":"Current approaches to the discovery of novel inhaled medicines","volume":"23","author":"Strong","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2022.09.011_bib188","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1258\/ebm.2010.010021","article-title":"Nanoparticle-induced pulmonary toxicity","volume":"235","author":"Li","year":"2010","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.apsb.2022.09.011_bib189","article-title":"Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction","author":"Lan","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2022.09.011_bib190","article-title":"Omicron: a heavily mutated SARS-CoV-2 variant\u00a0exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies","volume":"12","author":"Shah","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.09.011_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.894531","article-title":"Omicron spike protein has a positive electrostatic surface that promotes ACE2 recognition and antibody escape","volume":"2","author":"Gan","year":"2022","journal-title":"Front Virol"},{"key":"10.1016\/j.apsb.2022.09.011_bib192","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(22)00327-0","article-title":"Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods\u00a0of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study","volume":"399","author":"Menni","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.09.011_bib193","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","article-title":"Mechanisms of pharmaceutical aerosol deposition in the respiratory tract","volume":"15","author":"Cheng","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2022.09.011_bib194","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/acs.estlett.1c00337","article-title":"Development of electrospun nanofibrous filters for controlling coronavirus aerosols","volume":"8","author":"Shen","year":"2021","journal-title":"Environ Sci Technol Lett"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522004002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522004002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:00:11Z","timestamp":1761930011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522004002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":194,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2211383522004002"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.09.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Localized delivery of nanomedicine and antibodies for combating COVID-19","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}